Efficacy and safety of infliximab in patients with rheumatoid arthritis

Wen Zhang; Qun Shi; Dong Hai Wu; Chun De Bao; Nan Ping Yang; Zhan Guo Li; Ping Zhu; Xiao Zhang; Ci Bo Huang; Dong Yi He; Zhi Zhong Ye; Yi Tao; Yong Fei Fang; Jie Ruo Gu; Hua Xiang Wu; Ling Yun Sun; Xiu Yan Yang; Feng Huang; Hu Ji Xu; Dong Bao Zhao; Miao Jia Zhang; Yi Zheng; Mai Xing Ai; Jun Lu; Feng Chun Zhang

doi:10.3760/cma.j.issn.0376-2491.2009.27.002

Efficacy and safety of infliximab in patients with rheumatoid arthritis

Wen Zhang, Qun Shi, Dong Hai Wu, Chun De Bao, Nan Ping Yang, Zhan Guo Li, Ping Zhu, Xiao Zhang, Ci Bo Huang, Dong Yi He, Zhi Zhong Ye, Yi Tao, Yong Fei Fang, Jie Ruo Gu, Hua Xiang Wu, Ling Yun Sun, Xiu Yan Yang, Feng Huang, Hu Ji Xu, Dong Bao ZhaoMiao Jia Zhang, Yi Zheng, Mai Xing Ai, Jun Lu, Feng Chun Zhang

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Objective: To investigate the efficacy and safety of Infliximab (IFX) plus methotrexate (MTX) combination therapy in patients with rheumatoid arthritis (RA). Methods: Prospectively observe refractory RA patients who were treated with combination therapy of MTX and IFX. IFX was infused at the dosage of 3 mg/kg, in week 0, 2, 6, and then every 8 weeks. During treatment, clinical variables, disease activity and adverse effects were evaluated. Results: After treatment, 69.8%, 52.4%, 29.5% and 7.2% RA patients achieved ACR20, ACR50, ACR70 and ACR90 respectively. There were significant statistical differences in the changes of swollen joint counts, tender joint counts, VAS scale, patient's global assessment, and physician's global assessment before and after therapy. Conclusion: Infliximab plus MTX achieved significant efficacy and safety in refractory RA patients.

Original language	English
Pages (from-to)	1876-1880
Number of pages	5
Journal	National Medical Journal of China
Volume	89
Issue number	27
DOIs	https://doi.org/10.3760/cma.j.issn.0376-2491.2009.27.002
State	Published - 21 Jul 2009
Externally published	Yes

Keywords

Methotrexate
Rheumatoid arthritis
TNF inhibitor

Access to Document

10.3760/cma.j.issn.0376-2491.2009.27.002

Cite this

Zhang, W., Shi, Q., Wu, D. H., Bao, C. D., Yang, N. P., Li, Z. G., Zhu, P., Zhang, X., Huang, C. B., He, D. Y., Ye, Z. Z., Tao, Y., Fang, Y. F., Gu, J. R., Wu, H. X., Sun, L. Y., Yang, X. Y., Huang, F., Xu, H. J., ... Zhang, F. C. (2009). Efficacy and safety of infliximab in patients with rheumatoid arthritis. National Medical Journal of China, 89(27), 1876-1880. https://doi.org/10.3760/cma.j.issn.0376-2491.2009.27.002

@article{b732416826674cddbfef38e1e57b1770,

title = "Efficacy and safety of infliximab in patients with rheumatoid arthritis",

abstract = "Objective: To investigate the efficacy and safety of Infliximab (IFX) plus methotrexate (MTX) combination therapy in patients with rheumatoid arthritis (RA). Methods: Prospectively observe refractory RA patients who were treated with combination therapy of MTX and IFX. IFX was infused at the dosage of 3 mg/kg, in week 0, 2, 6, and then every 8 weeks. During treatment, clinical variables, disease activity and adverse effects were evaluated. Results: After treatment, 69.8%, 52.4%, 29.5% and 7.2% RA patients achieved ACR20, ACR50, ACR70 and ACR90 respectively. There were significant statistical differences in the changes of swollen joint counts, tender joint counts, VAS scale, patient's global assessment, and physician's global assessment before and after therapy. Conclusion: Infliximab plus MTX achieved significant efficacy and safety in refractory RA patients.",

keywords = "Methotrexate, Rheumatoid arthritis, TNF inhibitor",

author = "Wen Zhang and Qun Shi and Wu, {Dong Hai} and Bao, {Chun De} and Yang, {Nan Ping} and Li, {Zhan Guo} and Ping Zhu and Xiao Zhang and Huang, {Ci Bo} and He, {Dong Yi} and Ye, {Zhi Zhong} and Yi Tao and Fang, {Yong Fei} and Gu, {Jie Ruo} and Wu, {Hua Xiang} and Sun, {Ling Yun} and Yang, {Xiu Yan} and Feng Huang and Xu, {Hu Ji} and Zhao, {Dong Bao} and Zhang, {Miao Jia} and Yi Zheng and Ai, {Mai Xing} and Jun Lu and Zhang, {Feng Chun}",

year = "2009",

month = jul,

day = "21",

doi = "10.3760/cma.j.issn.0376-2491.2009.27.002",

language = "English",

volume = "89",

pages = "1876--1880",

journal = "National Medical Journal of China",

issn = "0376-2491",

publisher = "Chinese Medical Journals Publishing House Co.Ltd",

number = "27",

}

Zhang, W, Shi, Q, Wu, DH, Bao, CD, Yang, NP, Li, ZG, Zhu, P, Zhang, X, Huang, CB, He, DY, Ye, ZZ, Tao, Y, Fang, YF, Gu, JR, Wu, HX, Sun, LY, Yang, XY, Huang, F, Xu, HJ, Zhao, DB, Zhang, MJ, Zheng, Y, Ai, MX, Lu, J & Zhang, FC 2009, 'Efficacy and safety of infliximab in patients with rheumatoid arthritis', National Medical Journal of China, vol. 89, no. 27, pp. 1876-1880. https://doi.org/10.3760/cma.j.issn.0376-2491.2009.27.002

TY - JOUR

T1 - Efficacy and safety of infliximab in patients with rheumatoid arthritis

AU - Zhang, Wen

AU - Shi, Qun

AU - Wu, Dong Hai

AU - Bao, Chun De

AU - Yang, Nan Ping

AU - Li, Zhan Guo

AU - Zhu, Ping

AU - Zhang, Xiao

AU - Huang, Ci Bo

AU - He, Dong Yi

AU - Ye, Zhi Zhong

AU - Tao, Yi

AU - Fang, Yong Fei

AU - Gu, Jie Ruo

AU - Wu, Hua Xiang

AU - Sun, Ling Yun

AU - Yang, Xiu Yan

AU - Huang, Feng

AU - Xu, Hu Ji

AU - Zhao, Dong Bao

AU - Zhang, Miao Jia

AU - Zheng, Yi

AU - Ai, Mai Xing

AU - Lu, Jun

AU - Zhang, Feng Chun

PY - 2009/7/21

Y1 - 2009/7/21

N2 - Objective: To investigate the efficacy and safety of Infliximab (IFX) plus methotrexate (MTX) combination therapy in patients with rheumatoid arthritis (RA). Methods: Prospectively observe refractory RA patients who were treated with combination therapy of MTX and IFX. IFX was infused at the dosage of 3 mg/kg, in week 0, 2, 6, and then every 8 weeks. During treatment, clinical variables, disease activity and adverse effects were evaluated. Results: After treatment, 69.8%, 52.4%, 29.5% and 7.2% RA patients achieved ACR20, ACR50, ACR70 and ACR90 respectively. There were significant statistical differences in the changes of swollen joint counts, tender joint counts, VAS scale, patient's global assessment, and physician's global assessment before and after therapy. Conclusion: Infliximab plus MTX achieved significant efficacy and safety in refractory RA patients.

AB - Objective: To investigate the efficacy and safety of Infliximab (IFX) plus methotrexate (MTX) combination therapy in patients with rheumatoid arthritis (RA). Methods: Prospectively observe refractory RA patients who were treated with combination therapy of MTX and IFX. IFX was infused at the dosage of 3 mg/kg, in week 0, 2, 6, and then every 8 weeks. During treatment, clinical variables, disease activity and adverse effects were evaluated. Results: After treatment, 69.8%, 52.4%, 29.5% and 7.2% RA patients achieved ACR20, ACR50, ACR70 and ACR90 respectively. There were significant statistical differences in the changes of swollen joint counts, tender joint counts, VAS scale, patient's global assessment, and physician's global assessment before and after therapy. Conclusion: Infliximab plus MTX achieved significant efficacy and safety in refractory RA patients.

KW - Methotrexate

KW - Rheumatoid arthritis

KW - TNF inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84871309049&partnerID=8YFLogxK

U2 - 10.3760/cma.j.issn.0376-2491.2009.27.002

DO - 10.3760/cma.j.issn.0376-2491.2009.27.002

M3 - Article

C2 - 19953907

AN - SCOPUS:84871309049

SN - 0376-2491

VL - 89

SP - 1876

EP - 1880

JO - National Medical Journal of China

JF - National Medical Journal of China

IS - 27

ER -

Efficacy and safety of infliximab in patients with rheumatoid arthritis

Abstract

Keywords

Access to Document

Fingerprint

Cite this